Amedeo Smart

Free Medical Literature Service



Gastric Cancer

  Free Subscription

Articles published in
BMC Cancer
    August 2022
  1. NGUYEN MT, Huynh NNY, Nguyen DD, Ta NH, et al
    Vitamin D intake and gastric cancer in Viet Nam: a case-control study.
    BMC Cancer. 2022;22:838.
    >> Share

    July 2022
  2. ENDO S, Terazawa T, Goto M, Tanaka R, et al
    Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
    BMC Cancer. 2022;22:811.
    >> Share

  3. LE HX, Truong DTT, Tran LB, Le PH, et al
    A prospective cohort study on the association between waterpipe tobacco smoking and gastric cancer mortality in Northern Vietnam.
    BMC Cancer. 2022;22:803.
    >> Share

  4. NAM S, Lee Y, Kim JH
    RHOA protein expression correlates with clinical features in gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:798.
    >> Share

  5. YAMAGUCHI T, Kawakami H, Sakai D, Kurokawa Y, et al
    Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
    BMC Cancer. 2022;22:773.
    >> Share

  6. HE XJ, Ma YY, Yu S, Jiang XT, et al
    Retraction Note: Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho.
    BMC Cancer. 2022;22:766.
    >> Share

  7. YAN Y, Ma Z, Ji X, Liu J, et al
    A potential decision-making algorithm based on endoscopic ultrasound for staging early gastric cancer: a retrospective study.
    BMC Cancer. 2022;22:761.
    >> Share

  8. XU S, Chen W, Wang Y, Zhang Y, et al
    N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
    BMC Cancer. 2022;22:721.
    >> Share

    June 2022
  9. ZHOU M, Yang W, Xuan Y, Zou W, et al
    A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRac
    BMC Cancer. 2022;22:710.
    >> Share

    Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer.
    BMC Cancer. 2022;22:692.
    >> Share

  11. DU Y, Chen Y, Wu T, Fan X, et al
    miR-2682-3p antagonizes its host lncRNA-MIR137HG by interacting with the same target FUS to regulate the progression of gastric cancer.
    BMC Cancer. 2022;22:689.
    >> Share

  12. ZHANG X, Wang D, Sun T, Li W, et al
    Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection.
    BMC Cancer. 2022;22:684.
    >> Share

  13. VAN SCHOOTEN TS, Derks S, Jimenez-Marti E, Carneiro F, et al
    The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally.
    BMC Cancer. 2022;22:646.
    >> Share

  14. MIYATANI K, Sawata S, Makinoya M, Miyauchi W, et al
    Combined analysis of preoperative and postoperative lymphocyte-C-reactive protein ratio precisely predicts outcomes of patients with gastric cancer.
    BMC Cancer. 2022;22:641.
    >> Share

  15. WANG Y, Fang T, Wang Y, Yin X, et al
    Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.
    BMC Cancer. 2022;22:635.
    >> Share

  16. KINOSHITA J, Fushida S, Yamaguchi T, Moriyama H, et al
    Prognostic value of tumor-infiltrating CD163(+)macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment.
    BMC Cancer. 2022;22:608.
    >> Share

  17. TSUJIO G, Maruo K, Yamamoto Y, Sera T, et al
    Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.
    BMC Cancer. 2022;22:598.
    >> Share

    May 2022
  18. MATSUNAGA T, Saito H, Osaki T, Takahashi S, et al
    Impact of geriatric nutritional risk index on outcomes after gastrectomy in elderly patients with gastric cancer: a retrospective multicenter study in Japan.
    BMC Cancer. 2022;22:540.
    >> Share

  19. DOS SANTOS M, Lequesne J, Leconte A, Corbinais S, et al
    Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    BMC Cancer. 2022;22:537.
    >> Share

    April 2022
  20. KOOPAIE M, Ghafourian M, Manifar S, Younespour S, et al
    Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
    BMC Cancer. 2022;22:473.
    >> Share

  21. TAN Y, Chen Q, Pan S, An W, et al
    LMOD1, an oncogene associated with Lauren classification, regulates the metastasis of gastric cancer cells through the FAK-AKT/mTOR pathway.
    BMC Cancer. 2022;22:474.
    >> Share

  22. CHINEN T, Sasabuchi Y, Matsui H, Yamaguchi H, et al
    Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study.
    BMC Cancer. 2022;22:460.
    >> Share

  23. DALHAMMAR K, Kristensson J, Falkenback D, Rasmussen BH, et al
    Symptoms, problems and quality of life in patients newly diagnosed with oesophageal and gastric cancer - a comparative study of treatment strategy.
    BMC Cancer. 2022;22:434.
    >> Share

  24. LI PC, Huang RY, Yang YC, Hsieh KP, et al
    Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study.
    BMC Cancer. 2022;22:430.
    >> Share

  25. SHIN J, Shin DW, Lee J, Hwang J, et al
    Exploring socio-demographic, physical, psychological, and quality of life-related factors related with fear of cancer recurrence in stomach cancer survivors: a cross-sectional study.
    BMC Cancer. 2022;22:414.
    >> Share

  26. MATSUNAGA T, Saito H, Kuroda H, Osaki T, et al
    CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.
    BMC Cancer. 2022;22:418.
    >> Share

  27. KIM JH, Ryu MH, Park YS, Ma J, et al
    Predictive biomarkers for the efficacy of nivolumab as >/= 3(rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.
    BMC Cancer. 2022;22:378.
    >> Share

  28. LEI L, Li N, Yuan P, Liu D, et al
    A new risk model based on a 11-m(6)A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer.
    BMC Cancer. 2022;22:365.
    >> Share

    March 2022
  29. WANG Y, Zhu GQ, Tian D, Zhou CW, et al
    Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    BMC Cancer. 2022;22:316.
    >> Share

  30. GOTO K, Morimoto M, Osaki M, Tanio A, et al
    The impact of AMIGO2 on prognosis and hepatic metastasis in gastric cancer patients.
    BMC Cancer. 2022;22:280.
    >> Share

  31. EBERT K, Haffner I, Zwingenberger G, Keller S, et al
    Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
    BMC Cancer. 2022;22:254.
    >> Share

  32. JIANG Z, Zhou A, Sun Y, Zhang W, et al
    Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
    BMC Cancer. 2022;22:253.
    >> Share

  33. CHU XD, Lin ZB, Huang T, Ding H, et al
    Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer.
    BMC Cancer. 2022;22:250.
    >> Share

    February 2022
  34. LI N, Xiang X, Zhao D, Wang X, et al
    Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis.
    BMC Cancer. 2022;22:212.
    >> Share

  35. JIA Z, Zheng M, Jiang J, Cao D, et al
    Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.
    BMC Cancer. 2022;22:155.
    >> Share

  36. BRODSKY AS, Khurana J, Guo KS, Wu EY, et al
    Somatic mutations in collagens are associated with a distinct tumor environment and overall survival in gastric cancer.
    BMC Cancer. 2022;22:139.
    >> Share

    January 2022
  37. LIN L, Li H, Shi D, Liu Z, et al
    Depletion of C12orf48 inhibits gastric cancer growth and metastasis via up-regulating Poly r(C)-Binding Protein (PCBP) 1.
    BMC Cancer. 2022;22:123.
    >> Share

  38. SCHLINTL V, Huemer F, Rinnerthaler G, Melchardt T, et al
    Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
    BMC Cancer. 2022;22:51.
    >> Share

  39. SANO A, Sohda M, Nakazawa N, Ubukata Y, et al
    Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
    BMC Cancer. 2022;22:22.
    >> Share

  40. HENNESSY MA, Hamid M, Keegan NM, Corrigan L, et al
    Metastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials?
    BMC Cancer. 2022;22:3.
    >> Share

    December 2021
  41. SHI M, Yang Z, Lu S, Liu W, et al
    Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
    BMC Cancer. 2021;21:1344.
    >> Share

  42. CHEN Y, He J, Liu D, Xiao J, et al
    Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.
    BMC Cancer. 2021;21:1328.
    >> Share

  43. MA T, Wu Z, Zhang X, Xu H, et al
    Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma.
    BMC Cancer. 2021;21:1326.
    >> Share

  44. ZHANG S, Lv M, Cheng Y, Wang S, et al
    Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
    BMC Cancer. 2021;21:1324.
    >> Share

  45. SAITO H, Shimizu S, Shishido Y, Miyatani K, et al
    Prognostic significance of the combination of preoperative red cell distribution width and platelet distribution width in patients with gastric cancer.
    BMC Cancer. 2021;21:1317.
    >> Share

  46. HAN C, Zhang C, Wang H, Li K, et al
    Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    BMC Cancer. 2021;21:1312.
    >> Share

  47. JIANG L, Zhang Y, Guo L, Liu C, et al
    Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
    BMC Cancer. 2021;21:1290.
    >> Share

  48. XU X, Wang S, Wang H, Pan C, et al
    Hsa_circ_0008434 regulates USP9X expression by sponging miR-6838-5p to promote gastric cancer growth, migration and invasion.
    BMC Cancer. 2021;21:1289.
    >> Share

    November 2021
  49. YANZHANG W, Guanghua L, Zhihao Z, Zhixiong W, et al
    The risk of lymph node metastasis in gastric cancer conforming to indications of endoscopic resection and pylorus-preserving gastrectomy: a single-center retrospective study.
    BMC Cancer. 2021;21:1280.
    >> Share

  50. SUNDE B, Lindblad M, Malmstrom M, Hedberg J, et al
    Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish National Registry for Oesophageal and Gastric Cancer.
    BMC Cancer. 2021;21:1277.
    >> Share

  51. KINAMI S, Nakamura N, Miyashita T, Kitakata H, et al
    nPTD classification: an updated classification of gastric cancer location for function preserving gastrectomy based on physiological lymphatic flow.
    BMC Cancer. 2021;21:1231.
    >> Share

  52. MATSUNAGA T, Saito H, Miyauchi W, Shishido Y, et al
    Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
    BMC Cancer. 2021;21:1219.
    >> Share

  53. WEI J, Zeng Y, Gao X, Liu T, et al
    A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer.
    BMC Cancer. 2021;21:1221.
    >> Share

  54. WU WW, Zhang WH, Zhang WY, Liu K, et al
    The long-term survival outcomes of gastric cancer patients with total intravenous anesthesia or inhalation anesthesia: a single-center retrospective cohort study.
    BMC Cancer. 2021;21:1193.
    >> Share

  55. CHEN S, Lai H, Zhao J, Chen B, et al
    The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy.
    BMC Cancer. 2021;21:1183.
    >> Share

    October 2021
  56. LIU R, Yang X
    LncRNA LINC00342 promotes gastric cancer progression by targeting the miR-545-5p/CNPY2 axis.
    BMC Cancer. 2021;21:1163.
    >> Share

  57. GOTZE TO, Piso P, Lorenzen S, Bankstahl US, et al
    Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
    BMC Cancer. 2021;21:1158.
    >> Share

  58. WANG Q, Zhong J, Huang Q, Chen Z, et al
    A survival comparison of gastric mucin-producing adenocarcinoma to conventional adenocarcinoma: a SEER database analysis.
    BMC Cancer. 2021;21:1138.
    >> Share

  59. GIOMMONI E, Lavacchi D, Tirino G, Fornaro L, et al
    Results of the observational prospective RealFLOT study.
    BMC Cancer. 2021;21:1086.
    >> Share

  60. HIRAHARA N, Matsubara T, Kaji S, Yamamoto T, et al
    Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    BMC Cancer. 2021;21:1073.
    >> Share

    September 2021
  61. JIANG Q, Chen H, Tang Z, Sun J, et al
    Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer.
    BMC Cancer. 2021;21:1067.
    >> Share

  62. YURA M, Yoshikawa T, Wada T, Otsuki S, et al
    The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer.
    BMC Cancer. 2021;21:1056.
    >> Share

  63. LIU S, Xu M, Qiao X, Ji C, et al
    Prediction of serosal invasion in gastric cancer: development and validation of multivariate models integrating preoperative clinicopathological features and radiographic findings based on late arterial phase CT images.
    BMC Cancer. 2021;21:1038.
    >> Share

  64. CORDOVA-DELGADO M, Bravo ML, Cumsille E, Hill CN, et al
    A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    BMC Cancer. 2021;21:1030.
    >> Share

  65. PARK SH, Suh YS, Kim TH, Choi YH, et al
    Postoperative morbidity and quality of life between totally laparoscopic total gastrectomy and laparoscopy-assisted total gastrectomy: a propensity-score matched analysis.
    BMC Cancer. 2021;21:1016.
    >> Share

    August 2021
  66. CHEN L, Zhang C, Yao Z, Cui M, et al
    Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.
    BMC Cancer. 2021;21:974.
    >> Share

  67. LI HQ, Xue H, Yuan H, Wan GY, et al
    Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment.
    BMC Cancer. 2021;21:959.
    >> Share

  68. UOZUMI T, Sumiyoshi T, Tomita Y, Tokuchi K, et al
    Does second-look endoscopy reduce the bleeding after gastric endoscopic submucosal dissection for patients receiving antithrombotic therapy?
    BMC Cancer. 2021;21:946.
    >> Share

  69. NING G, Zhu Q, Kang W, Lee H, et al
    A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
    BMC Cancer. 2021;21:923.
    >> Share

  70. WANG J, Xu P, Hao Y, Yu T, et al
    Interaction between DNMT3B and MYH11 via hypermethylation regulates gastric cancer progression.
    BMC Cancer. 2021;21:914.
    >> Share

    July 2021
  71. YEN CC, Shan YS, Chao YJ, Liao TK, et al
    Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
    BMC Cancer. 2021;21:796.
    >> Share

  72. ZHOU YJ, Lu XF, Meng JL, Wang XY, et al
    Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
    BMC Cancer. 2021;21:771.
    >> Share

    June 2021
  73. SANTERO M, Perez-Bracchiglione J, Acosta-Dighero R, Meade AG, et al
    Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews.
    BMC Cancer. 2021;21:712.
    >> Share

  74. YE Z, Zeng Y, Wei S, Wang Y, et al
    Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
    BMC Cancer. 2021;21:702.
    >> Share

  75. LU XQ, Zhang JQ, Zhang SX, Qiao J, et al
    Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.
    BMC Cancer. 2021;21:697.
    >> Share

  76. WU R, Guo S, Lai S, Pan G, et al
    A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer.
    BMC Cancer. 2021;21:684.
    >> Share

  77. ZHANG J, Lv W, Liu Y, Fu W, et al
    LINC_00355 promotes gastric cancer progression by upregulating PHF19 expression through sponging miR-15a-5p.
    BMC Cancer. 2021;21:657.
    >> Share

    May 2021
  78. DAI J, Nishi A, Li ZX, Zhang Y, et al
    DNA methylation signatures associated with prognosis of gastric cancer.
    BMC Cancer. 2021;21:610.
    >> Share

  79. RUSTGI SD, Oh A, Yang JY, Kang D, et al
    Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
    BMC Cancer. 2021;21:597.
    >> Share

  80. CHEN Y, Hu N, Liao L, Yu K, et al
    ABO genotypes and the risk of esophageal and gastric cancers.
    BMC Cancer. 2021;21:589.
    >> Share

  81. O'CONNOR L, Smyth E, Bennett AE, Smith V, et al
    Identifying outcomes reported in exercise interventions in oesophagogastric cancer survivors: a systematic review.
    BMC Cancer. 2021;21:586.
    >> Share

  82. CHUN SH, Kim EY, Yoon JS, Won HS, et al
    Prognostic value of noggin protein expression in patients with resected gastric cancer.
    BMC Cancer. 2021;21:558.
    >> Share

  83. NIE C, Han X, Wei R, Leonteva A, et al
    Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer.
    BMC Cancer. 2021;21:551.
    >> Share

  84. CHEN J, Xia YJ, Liu TY, Lai YH, et al
    Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data.
    BMC Cancer. 2021;21:532.
    >> Share

    April 2021
  85. LIU N, Wu Y, Cheng W, Wu Y, et al
    Identification of novel prognostic biomarkers by integrating multi-omics data in gastric cancer.
    BMC Cancer. 2021;21:460.
    >> Share

  86. ZHONG X, Xuan F, Qian Y, Pan J, et al
    A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.
    BMC Cancer. 2021;21:455.
    >> Share

  87. LIU L, Zhang C, Wang J, Liu X, et al
    A high level of lncFGD5-AS1 inhibits epithelial-to-Mesenchymal transition by regulating the miR-196a-5p/SMAD6/BMP axis in gastric Cancer.
    BMC Cancer. 2021;21:453.
    >> Share

  88. YU J, Jung J, Park SR, Ryu MH, et al
    Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer.
    BMC Cancer. 2021;21:413.
    >> Share

  89. YU Y, Xie Z, Zhao M, Lian X, et al
    Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
    BMC Cancer. 2021;21:368.
    >> Share

    March 2021
  90. KIM TH, Do Cho H, Choi YW, Lee HW, et al
    Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data.
    BMC Cancer. 2021;21:325.
    >> Share

  91. CAI Z, Song H, Fingerhut A, Sun J, et al
    A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer.
    BMC Cancer. 2021;21:319.
    >> Share

  92. LIANG Y, Zhao L, Chen H, Lin T, et al
    Correction to: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
    BMC Cancer. 2021;21:298.
    >> Share

  93. JI J, Chen J, Wang A, Zhang W, et al
    KK-LC-1 may be an effective prognostic biomarker for gastric cancer.
    BMC Cancer. 2021;21:267.
    >> Share

  94. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    >> Share

  95. HE P, Cheng S, Hu F, Ma Z, et al
    Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.
    BMC Cancer. 2021;21:252.
    >> Share

  96. GE Y, Wei F, Du G, Fei G, et al
    The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    BMC Cancer. 2021;21:240.
    >> Share

  97. OKAGAWA Y, Sumiyoshi T, Kondo H, Tomita Y, et al
    Comparison of clinicopathological features and long-term prognosis between mixed predominantly differentiated-type and pure differentiated-type early gastric cancer.
    BMC Cancer. 2021;21:235.
    >> Share

  98. EHARA T, Uehara T, Nakajima T, Kinugawa Y, et al
    LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma.
    BMC Cancer. 2021;21:228.
    >> Share

  99. FAN B, Bu Z, Zhang J, Zong X, et al
    Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery.
    BMC Cancer. 2021;21:216.
    >> Share

  100. LIM JH, Song JH, Chung SJ, Chung GE, et al
    Characteristics of interval gastric neoplasms detected within two years after negative screening endoscopy among Koreans.
    BMC Cancer. 2021;21:218.
    >> Share

    February 2021
  101. LIANG Y, Zhao L, Chen H, Lin T, et al
    Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
    BMC Cancer. 2021;21:196.
    >> Share

  102. CHEN XJ, Chen GM, Wei YC, Yu H, et al
    Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis.
    BMC Cancer. 2021;21:188.
    >> Share

  103. KIM KW, Lee K, Lee JB, Park T, et al
    Preoperative nutritional risk index and postoperative one-year skeletal muscle loss can predict the prognosis of patients with gastric adenocarcinoma: a registry-based study.
    BMC Cancer. 2021;21:157.
    >> Share

  104. BAEG K, Harris C, Naparst MS, Ahn E, et al
    Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    BMC Cancer. 2021;21:146.
    >> Share

    January 2021
  105. ITO A, Kagawa S, Sakamoto S, Kuwada K, et al
    Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation.
    BMC Cancer. 2021;21:102.
    >> Share

  106. OKUBO K, Arigami T, Matsushita D, Kijima T, et al
    Clinical impact of creatine phosphokinase and c-reactive protein as predictors of postgastrectomy complications in patients with gastric cancer.
    BMC Cancer. 2021;21:95.
    >> Share

  107. EMBAYE KS, Zhang C, Ghebrehiwet MA, Wang Z, et al
    Clinico-pathologic determinants of non-e-curative outcome following en-bloc endoscopic submucosal dissection in patients with early gastric neoplasia.
    BMC Cancer. 2021;21:92.
    >> Share

  108. CHENG X, Wu D, Xu N, Chen L, et al
    Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    BMC Cancer. 2021;21:56.
    >> Share

  109. TONG Y, Zhao Y, Shan Z, Zhang J, et al
    CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:4.
    >> Share

  110. TAO S, Gu J, Wang Q, Zheng L, et al
    Translational control of Bcl-2 promotes apoptosis of gastric carcinoma cells.
    BMC Cancer. 2021;21:12.
    >> Share

  111. WANG X, Li S, Sun Y, Li K, et al
    The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    BMC Cancer. 2021;21:20.
    >> Share

  112. SMITH-PALMER J, Leeuwenkamp OR, Virk J, Reed N, et al
    Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.
    BMC Cancer. 2021;21:10.
    >> Share

    November 2020
  113. EBERT K, Zwingenberger G, Barbaria E, Keller S, et al
    Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
    BMC Cancer. 2020;20:1127.
    >> Share

  114. YU P, Ye Z, Dai G, Zhang Y, et al
    Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    BMC Cancer. 2020;20:1108.
    >> Share

  115. WU R, Yang C, Ji L, Fan ZN, et al
    Prevalence of gastric cancer precursors in gastroscopy-screened adults by family history of gastric cancer and of cancers other than gastric.
    BMC Cancer. 2020;20:1110.
    >> Share

  116. OKUNAKA M, Kotani D, Demachi K, Kawazoe A, et al
    Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    BMC Cancer. 2020;20:1111.
    >> Share

  117. MASUI T, Ito T, Komoto I, Uemoto S, et al
    Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    BMC Cancer. 2020;20:1104.
    >> Share

    October 2020
  118. EBERT K, Zwingenberger G, Barbaria E, Keller S, et al
    Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
    BMC Cancer. 2020;20:1039.
    >> Share

  119. FUJIMORI D, Kinoshita J, Yamaguchi T, Nakamura Y, et al
    Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer.
    BMC Cancer. 2020;20:1014.
    >> Share

  120. WANG JB, Xue Z, Lu J, He QL, et al
    Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series.
    BMC Cancer. 2020;20:1002.
    >> Share

  121. XUE X, Huang J, Yu K, Chen X, et al
    YB-1 transferred by gastric cancer exosomes promotes angiogenesis via enhancing the expression of angiogenic factors in vascular endothelial cells.
    BMC Cancer. 2020;20:996.
    >> Share

    September 2020
  122. SONKAR C, Verma T, Chatterji D, Jain AK, et al
    Status of kinases in Epstein-Barr virus and Helicobacter pylori Coinfection in gastric Cancer cells.
    BMC Cancer. 2020;20:925.
    >> Share

  123. LORENZEN S, Biederstadt A, Ronellenfitsch U, Reissfelder C, et al
    RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    BMC Cancer. 2020;20:886.
    >> Share

  124. JIN X, Dai L, Ma Y, Wang J, et al
    Homeobox proteins are potential biomarkers and therapeutic targets in gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:866.
    >> Share

  125. YOON JY, Brezden-Masley C, Streutker CJ
    Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma - significance of potentially retained stemness.
    BMC Cancer. 2020;20:860.
    >> Share

    August 2020
  126. ZHU L, Xu Z, Wu Y, Liu P, et al
    Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study.
    BMC Cancer. 2020;20:827.
    >> Share

  127. ZHENG Z, Yin J, Li Z, Ye Y, et al
    Protocol for expanded indications of endoscopic submucosal dissection for early gastric cancer in China: a multicenter, ambispective, observational, open-cohort study.
    BMC Cancer. 2020;20:801.
    >> Share

  128. LEERS JM, Knepper L, van der Veen A, Schroder W, et al
    The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II.
    BMC Cancer. 2020;20:781.
    >> Share

  129. CHEN J, Wang A, Ji K, Bu Z, et al
    Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study.
    BMC Cancer. 2020;20:777.
    >> Share

  130. JIANG H, Zheng Y, Qian J, Mao C, et al
    Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    BMC Cancer. 2020;20:760.
    >> Share

  131. SHADMANI FK, Farzadfar F, Yoosefi M, Mansori K, et al
    Premature mortality of gastrointestinal cancer in Iran: trends and projections 2001-2030.
    BMC Cancer. 2020;20:752.
    >> Share

    July 2020
  132. MATSUMOTO T, Yamamoto Y, Kuriona Y, Okazaki U, et al
    Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
    BMC Cancer. 2020;20:684.
    >> Share

  133. YANG C, Shi Y, Xie S, Chen J, et al
    Short-term outcomes of robotic- versus laparoscopic-assisted Total Gastrectomy for advanced gastric Cancer: a propensity score matching study.
    BMC Cancer. 2020;20:669.
    >> Share

  134. ZHOU K, Wang A, Ao S, Chen J, et al
    The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis.
    BMC Cancer. 2020;20:671.
    >> Share

  135. LIN JL, Lin JX, Zheng CH, Li P, et al
    Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
    BMC Cancer. 2020;20:638.
    >> Share

  136. EBRAHIMI GHAHNAVIEH L, Tabatabaeian H, Ebrahimi Ghahnavieh Z, Honardoost MA, et al
    Fluctuating expression of miR-584 in primary and high-grade gastric cancer.
    BMC Cancer. 2020;20:621.
    >> Share

    June 2020
  137. PENG Z, Guan Q, Luo J, Deng W, et al
    Sophoridine exerts tumor-suppressive activities via promoting ESRRG-mediated beta-catenin degradation in gastric cancer.
    BMC Cancer. 2020;20:582.
    >> Share

  138. REHKAEMPER J, Korenkov M, Quaas A, Rueschoff J, et al
    Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
    BMC Cancer. 2020;20:587.
    >> Share

  139. HIRATA K, Hamamoto Y, Ando M, Imamura CK, et al
    Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II
    BMC Cancer. 2020;20:548.
    >> Share

  140. RICHARDS HS, Blazeby JM, Portal A, Harding R, et al
    A real-time electronic symptom monitoring system for patients after discharge following surgery: a pilot study in cancer-related surgery.
    BMC Cancer. 2020;20:543.
    >> Share

  141. SUN QH, Yin ZX, Li Z, Tian SB, et al
    miR-874 inhibits gastric cancer cell proliferation by targeting SPAG9.
    BMC Cancer. 2020;20:522.
    >> Share

  142. TOYOKAWA T, Muguruma K, Yoshii M, Tamura T, et al
    Clinical significance of prognostic inflammation-based and/or nutritional markers in patients with stage III gastric cancer.
    BMC Cancer. 2020;20:517.
    >> Share

  143. GU E, Song W, Liu A, Wang H, et al
    SCDb: an integrated database of stomach cancer.
    BMC Cancer. 2020;20:490.
    >> Share

  144. TAVAKOLI A, Monavari SH, Solaymani Mohammadi F, Kiani SJ, et al
    Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:493.
    >> Share

  145. TINTELNOT J, Goekkurt E, Binder M, Thuss-Patience P, et al
    Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    BMC Cancer. 2020;20:503.
    >> Share

    May 2020
  146. SUN KY, Hu HT, Chen SL, Ye JN, et al
    CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer.
    BMC Cancer. 2020;20:468.
    >> Share

  147. KPOGHOMOU MA, Wang J, Wang T, Jin G, et al
    Association of Helicobacter pylori babA2 gene and gastric cancer risk: a meta-analysis.
    BMC Cancer. 2020;20:465.
    >> Share

  148. LI WH, Zhang JY, Liu WH, Chen XX, et al
    Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis.
    BMC Cancer. 2020;20:414.
    >> Share

  149. O'NEILL L, Guinan E, Doyle S, Connolly D, et al
    Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre II): a protocol for a randomized controlled trial.
    BMC Cancer. 2020;20:415.
    >> Share

  150. TANG S, Lin L, Cheng J, Zhao J, et al
    The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer.
    BMC Cancer. 2020;20:382.
    >> Share

    April 2020
  151. NAKAMURA N, Kinami S, Tomita Y, Miyata T, et al
    The neutrophil/lymphocyte ratio as a predictor of successful conversion surgery for stage IV gastric cancer: a retrospective study.
    BMC Cancer. 2020;20:363.
    >> Share

  152. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
    Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
    BMC Cancer. 2020;20:345.
    >> Share

  153. KAWAI S, Fukuda N, Yamamoto S, Mitani S, et al
    Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.
    BMC Cancer. 2020;20:338.
    >> Share

  154. YOON SJ, Park J, Shin Y, Choi Y, et al
    Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model.
    BMC Cancer. 2020;20:314.
    >> Share

    March 2020
  155. BEEHARRY MK, Ni ZT, Yang ZY, Zheng YN, et al
    Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gas
    BMC Cancer. 2020;20:224.
    >> Share

  156. WANG M, Li Z, Peng Y, Fang J, et al
    Identification of immune cells and mRNA associated with prognosis of gastric cancer.
    BMC Cancer. 2020;20:206.
    >> Share

  157. KONO Y, Saito H, Miyauchi W, Shimizu S, et al
    Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients.
    BMC Cancer. 2020;20:175.
    >> Share

  158. CHOI JH, Choi YW, Kang SY, Jeong GS, et al
    Combination versus single-agent as palliative chemotherapy for gastric cancer.
    BMC Cancer. 2020;20:167.
    >> Share

    February 2020
  159. ZHENG G, Liu J, Guo Y, Wang F, et al
    Necessity of prophylactic splenic hilum lymph node clearance for middle and upper third gastric cancer: a network meta-analysis.
    BMC Cancer. 2020;20:149.
    >> Share

    January 2020
  160. HU X, Zhao F, Yu H, Luo Y, et al
    GC-PROM: validation of a patient-reported outcomes measure for Chinese patients with gastric cancer.
    BMC Cancer. 2020;20:41.
    >> Share

  161. MOORE A, Hikri E, Goshen-Lago T, Barkan T, et al
    Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
    BMC Cancer. 2020;20:34.
    >> Share

  162. LIN JX, Lin JP, Xie JW, Wang JB, et al
    Complete blood count-based inflammatory score (CBCS) is a novel prognostic marker for gastric cancer patients after curative resection.
    BMC Cancer. 2020;20:11.
    >> Share

  163. WANG CY, Yang J, Zi H, Zheng ZL, et al
    Nomogram for predicting the survival of gastric adenocarcinoma patients who receive surgery and chemotherapy.
    BMC Cancer. 2020;20:10.
    >> Share

    December 2019
  164. BEEHARRY MK, Zhu ZL, Liu WT, Yao XX, et al
    Correction to: Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study.
    BMC Cancer. 2019;19:1256.
    >> Share

  165. SHIN K, Park SJ, Lee J, Park CH, et al
    Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    BMC Cancer. 2019;19:1232.
    >> Share

  166. KOSUGA T, Konishi T, Kubota T, Shoda K, et al
    Clinical significance of neutrophil-to-lymphocyte ratio as a predictor of lymph node metastasis in gastric cancer.
    BMC Cancer. 2019;19:1187.
    >> Share

    November 2019
  167. ZHENG HL, Lu J, Xie JW, Wang JB, et al
    Exploring the value of new preoperative inflammation prognostic score: white blood cell to hemoglobin for gastric adenocarcinoma patients.
    BMC Cancer. 2019;19:1127.
    >> Share

  168. GUO X, Zhao F, Ma X, Shen G, et al
    A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:1125.
    >> Share

  169. WANG X, Zhao J, Fairweather M, Yang T, et al
    Optimal treatment for elderly patients with resectable proximal gastric carcinoma: a real world study based on National Cancer Database.
    BMC Cancer. 2019;19:1079.
    >> Share

  170. LIN JX, Wang ZK, Wang W, Desiderio J, et al
    Risk factors of lymph node metastasis or lymphovascular invasion for early gastric cancer: a practical and effective predictive model based on international multicenter data.
    BMC Cancer. 2019;19:1048.
    >> Share

    October 2019
  171. LIU P, McMenamin UC, Spence AD, Johnston BT, et al
    Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study.
    BMC Cancer. 2019;19:1017.
    >> Share

  172. BU X, Zhang A, Chen Z, Zhang X, et al
    Migration of gastric cancer is suppressed by recombinant Newcastle disease virus (rL-RVG) via regulating alpha7-nicotinic acetylcholine receptors/ERK- EMT.
    BMC Cancer. 2019;19:976.
    >> Share

  173. MASUDA K, Shoji H, Nagashima K, Yamamoto S, et al
    Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    BMC Cancer. 2019;19:974.
    >> Share

  174. TANIOKA H, Nagasaka T, Uno F, Inoue M, et al
    The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
    BMC Cancer. 2019;19:941.
    >> Share

    September 2019
  175. YEO ST, Bray N, Haboubi H, Hoare Z, et al
    Endoscopic ultrasound staging in patients with gastro-oesophageal cancers: a systematic review of economic evidence.
    BMC Cancer. 2019;19:900.
    >> Share

  176. LIN JL, Lin JX, Li P, Xie JW, et al
    Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study.
    BMC Cancer. 2019;19:873.
    >> Share

  177. KIM H, Son SM, Woo CG, Lee OJ, et al
    Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions.
    BMC Cancer. 2019;19:834.
    >> Share

    August 2019
  178. MA T, Wu ZJ, Xu H, Wu CH, et al
    Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy.
    BMC Cancer. 2019;19:852.
    >> Share

  179. CHENG Y, Xiao Y, Zhou R, Liao Y, et al
    Prognostic significance of helicobacter pylori-infection in gastric diffuse large B-cell lymphoma.
    BMC Cancer. 2019;19:842.
    >> Share

    May 2019
  180. WAGNER AD, Grabsch HI, Mauer M, Marreaud S, et al
    EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction
    BMC Cancer. 2019;19:494.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016